Clôture précédente | 0,0500 |
Ouverture | 0,0500 |
Offre | 0,0000 |
Vente | 0,0000 |
Prix d’exercice | 2,50 |
Date d’expiration | 2024-05-17 |
Var. jour | 0,0400 - 0,0900 |
Gamme de contrats | S.O. |
Volume | |
Position de place | 173 |
NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies.